TMCnet News
Enlivex Therapeutics to Present at The 2019 Jefferies Global Healthcare ConferenceNes-Ziona, Israel, May 30, 2019 (GLOBE NEWSWIRE) -- ?Enlivex Therapeutics Ltd. (Nasdaq:ENLV), a clinical-stage immunotherapy company, today announced that company management will make a corporate presentation at the Jefferies Global Healthcare 2019 conference being held in New York City. The presentation is scheduled for June 7th 2019 at 1:00pm Eastern Time. ALLOCETRA™ by Enlivex is a novel immunotherapy based on a unique mechanism of action that targets life threatening diseases that are defined as “unmet medical needs” such as preventing or treating complications associated with bone marrow translants (“BMT”) and/or hematopoietic stem cell transplants (“HSCT); organ dysfunction and acute multiple organ failure associated with sepsis and enablement of an effective treatment of solid tumors via immune checkpoint rebalancing. For more information about the Jefferies Global Healthcare 2019 conference, visit http://www.jefferies.com/IdeasAndPerspectives/Conferences/325/060419 ABOUT ENLIVEX
ENLIVEX CONTACT: Shachar Shlosberger, CFO Enlivex Therapeutics, Ltd. [email protected] |